Cargando…

Clinical and Nonclinical Disposition and In Vitro Drug-Drug Interaction Potential of Felcisetrag, a Highly Selective and Potent 5-HT(4) Receptor Agonist

BACKGROUND AND OBJECTIVE: Felcisetrag (previously TAK-954 or TD-8954) is a highly selective and potent 5-HT(4) receptor agonist in clinical development for prophylaxis and treatment of postoperative gastrointestinal dysfunction (POGD). The rat, dog, and human absorption, distribution, metabolism, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pusalkar, Sandeepraj, Chowdhury, Swapan K., Czerniak, Richard, Zhu, Xiaochun, Li, Yuexian, Balani, Suresh K., Ramsden, Diane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050781/ https://www.ncbi.nlm.nih.gov/pubmed/35157234 http://dx.doi.org/10.1007/s13318-021-00751-8

Ejemplares similares

Randomised study: effects of the 5‐HT(4) receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis
por: Chedid, Victor, et al.
Publicado: (2021)

The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK‐954)
por: Czerniak, Richard, et al.
Publicado: (2022)

Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication
por: Dambra, Richard, et al.
Publicado: (2022)

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [(14)C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors
por: Gupta, Neeraj, et al.
Publicado: (2017)

Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
por: Fisher, J. Edward
Publicado: (2021)

Sex Differences in Drug Disposition
por: Soldin, Offie P., et al.
Publicado: (2011)

Modeling and Simulation at the Interface of Nonclinical and Early Clinical Drug Development
por: Visser, S A G, et al.
Publicado: (2013)

Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data
por: Li, Chunze, et al.
Publicado: (2019)

Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury?
por: Daly, Ann K.
Publicado: (2016)

Human Neural Stem Cell-Based Drug Product: Clinical and Nonclinical Characterization
por: Profico, Daniela Celeste, et al.
Publicado: (2022)

Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711
por: Lindström, Erik, et al.
Publicado: (2018)

Treatment With Antipsychotics in Pregnancy: Changes in Drug Disposition
por: Westin, Andreas A., et al.
Publicado: (2017)

Racial Disparity in Drug Disposition in the Digestive Tract
por: Gao, Song, et al.
Publicado: (2021)

Drug-disease interaction: Clinical consequences of inflammation on drugs action and disposition
por: Abdallah, Yasmeen El Hajj, et al.
Publicado: (2023)

Oral Drug Absorption and Drug Disposition in Critically Ill Cardiac Patients
por: Harnisch, Lars-Olav, et al.
Publicado: (2023)

Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability
por: Tsunoda, Shirley M., et al.
Publicado: (2021)

Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
por: Singh, Shweta, et al.
Publicado: (2022)

The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties
por: Beattie, David T., et al.
Publicado: (2011)

Identification of a Potent and Selective 5-HT(1A) Receptor Agonist with In Vitro and In Vivo Antinociceptive Activity
por: Linciano, Pasquale, et al.
Publicado: (2020)

Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan
por: Kubota, Sachie, et al.
Publicado: (2016)

In vitro and in vivo drug disposition of cilengitide in animals and human
por: Dolgos, Hugues, et al.
Publicado: (2016)

Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics
por: Mooij, Miriam G., et al.
Publicado: (2015)

Challenges and advances in the assessment of the disposition of antibody‐drug conjugates
por: Kamath, Amrita V., et al.
Publicado: (2015)

Editorial of Special Issue on Drug Metabolism and Disposition in Diseases
por: Xie, Wen
Publicado: (2020)

Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring
por: Lemmens, Glenn, et al.
Publicado: (2021)

Intracellular drug bioavailability: a new predictor of system dependent drug disposition
por: Mateus, André, et al.
Publicado: (2017)

Pharmacogenomic network analysis of the gene-drug interaction landscape underlying drug disposition
por: Zhou, Yitian, et al.
Publicado: (2019)

International consortium for innovation and quality: An industry perspective on the nonclinical and early clinical development of intravitreal drugs
por: Pruimboom‐Brees, Ingrid M., et al.
Publicado: (2023)

An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials
por: Henderson, C.J., et al.
Publicado: (2019)

Discovery of Novel Indolealkylpiperazine Derivatives as Potent 5-HT(1A) Receptor Agonists for the Potential Future Treatment of Depression
por: Zhu, Chen, et al.
Publicado: (2020)

A Tutorial on Target-Mediated Drug Disposition (TMDD) Models
por: Dua, P, et al.
Publicado: (2015)

Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition
por: Lozano, Elisa, et al.
Publicado: (2018)

Preclinical disposition of MGS0274 besylate, a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophrenia
por: Kinoshita, Kohnosuke, et al.
Publicado: (2019)

Reduced and optimized trial designs for drugs described by a target mediated drug disposition model
por: Brekkan, A., et al.
Publicado: (2018)

5-HT1A agonists, 5-HT3 antagonists and benzodiazepines : their comparative behavioural pharmacology /
Publicado: (1991)

Principles of drug disposition in domestic animals the basis of veterinary clinical pharmacology /
por: Baggot, J. Desmond
Publicado: (1977)

Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification
por: Peletier, Lambertus A., et al.
Publicado: (2012)

Pathophysiological changes that affect drug disposition in protein-energy malnourished children
por: Oshikoya, Kazeem A, et al.
Publicado: (2009)

Induction of Drug Transporters Alters Disposition of Risperidone - A Study in Mice
por: Holthoewer, David, et al.
Publicado: (2010)

Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis
por: Sahota, T, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ajbjhsj7idl9cjelgtqr6eaesj